[HTML][HTML] Case report: Severe central nervous system manifestations associated with aberrant efavirenz metabolism in children: the role of CYP2B6 genetic variation
F Pinillos, C Dandara, M Swart, R Strehlau… - BMC infectious …, 2015 - Springer
Background Efavirenz, widely used as part of antiretroviral drug regimens in the treatment of
paediatric human immunodeficiency virus infection, has central nervous system side effects …
paediatric human immunodeficiency virus infection, has central nervous system side effects …
Absence seizures associated with efavirenz initiation
R Strehlau, L Martens, A Coovadia… - The Pediatric …, 2011 - journals.lww.com
Efavirenz, used in treating pediatric human immunodeficiency virus infection, has central
nervous system side effects. We report on a 5-year-old girl with perinatally acquired human …
nervous system side effects. We report on a 5-year-old girl with perinatally acquired human …
Psychosis in a 12-year-old HIV-positive girl with an increased serum concentration of efavirenz
EA Lowenhaupt, K Matson, B Qureishi… - Clinical infectious …, 2007 - academic.oup.com
Clearance and adverse effects of efavirenz are associated with CYP2B6-G516T
polymorphism. Little is known about the prevalence of genotypes and implications for …
polymorphism. Little is known about the prevalence of genotypes and implications for …
Plasma efavirenz concentrations and the association with CYP2B6-516 G >T polymorphism in HIV-infected Thai children
T Puthanakit, P Tanpaiboon, L Aurpibul… - Antiviral …, 2009 - journals.sagepub.com
Background Concerns have been raised about the possibility of subtherapeutic efavirenz
(EFV) plasma levels in children with the current dosing guideline. Single nucleotide …
(EFV) plasma levels in children with the current dosing guideline. Single nucleotide …
Pharmacogenetics of the late-onset efavirenz neurotoxicity syndrome (LENS)
Background The late-onset efavirenz neurotoxicity syndrome (LENS) presents as ataxia
and/or encephalopathy with supratherapeutic efavirenz plasma concentrations (> 4 µg/mL) …
and/or encephalopathy with supratherapeutic efavirenz plasma concentrations (> 4 µg/mL) …
Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism
A Saitoh, CV Fletcher, R Brundage… - JAIDS Journal of …, 2007 - journals.lww.com
Background: The CYP2B6-G516T polymorphism has been shown to alter plasma efavirenz
(EFV) concentrations in adults. The impact of CYP2B6-G516T polymorphisms on EFV …
(EFV) concentrations in adults. The impact of CYP2B6-G516T polymorphisms on EFV …
Population pharmacokinetics analysis to inform efavirenz dosing recommendations in pediatric HIV patients aged 3 months to 3 years
M Luo, S Chapel, H Sevinsky, I Savant… - Antimicrobial agents …, 2016 - Am Soc Microbiol
Efavirenz (EFV) is a nonnucleoside reverse transcriptase inhibitor approved worldwide for
the treatment of HIV in adults and children over 3 years of age or weighing over 10 kg. Only …
the treatment of HIV in adults and children over 3 years of age or weighing over 10 kg. Only …
[HTML][HTML] Neuropsychiatric and neurocognitive manifestations in hiv-infected children treated with efavirenz in South Africa—a retrospective case series
Background: Efavirenz is associated with transient neuropsychiatric manifestations but the
impact on neurocognition in children is unknown. Genetically slow metabolizers of efavirenz …
impact on neurocognition in children is unknown. Genetically slow metabolizers of efavirenz …
[HTML][HTML] Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic …
S Soeria-Atmadja, E Österberg, LL Gustafsson… - PloS one, 2017 - journals.plos.org
Background Approximately 2.6 million children live with HIV globally, and efavirenz (EFV) is
one of the most widely used antiretroviral agents for HIV treatment in children and adults …
one of the most widely used antiretroviral agents for HIV treatment in children and adults …
Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6* 6 and* 26
H Gatanaga, T Hayashida, K Tsuchiya… - Clinical infectious …, 2007 - academic.oup.com
Background. Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6),
and high plasma concentrations of the drug are associated with a G→ T polymorphism at …
and high plasma concentrations of the drug are associated with a G→ T polymorphism at …